Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SIAL. Sigma® Life Science Launches Novel, Affordable Pluripotent Stem Cell Culture Medium
http://finance.yahoo.com/news/sigma-life-science-launches-novel-110000623.html
SRPT. Sarepta Therapeutics Receives Notice From Department of Defense for Termination of Ebola Therapeutic Program
http://finance.yahoo.com/news/sarepta-therapeutics-receives-notice-department-110500046.html
SRPT. before/open.Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy
Eteplirsen Results in an Increase in Novel Dystrophin to 47% of Normal After 48 Weeks of Treatment; Eteplirsen 50mg/kg Weekly Demonstrates Continued Clinical Benefit of 89.4 Meters in 6-Minute Walk Test Over Placebo/Delayed Treatment Cohort; No Eteplirsen-Related Adverse Events Through Week 48
http://finance.yahoo.com/news/sarepta-therapeutics-announces-eteplirsen-meets-110000135.html
GNVC--quick look:
21.5m market cap
13.5m revenue
diluted eps -.84
total cash 21m
Q yoy growth -46%
pps 9/11 2.50-3.00
os 13m float 11m
http://finance.yahoo.com/q/ks?s=GNVC+Key+Statistics
http://www.genvec.com/
Business Summary
GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines. The company develops and commercializes its product candidates through collaborations with various companies and organizations, including Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of various human and animal health concerns. Its development programs address various therapeutic areas, such as hearing loss and balance disorders; and vaccines against infectious diseases comprising respiratory syncytial virus, herpes simplex virus, dengue fever, and malaria. The company is also involved in developing vaccines against foot-and-mouth disease. GenVec, Inc. was founded in 1992 and is based in Gaithersburg, Maryland.
Kansas. "Carry On My Wayward Son".
SRPT. Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study
http://finance.yahoo.com/news/sarepta-therapeutics-announces-conference-call-203000553.html
HPTX. Hyperion Therapeutics to Report Results of HALT-HE Study at AASLD Plenary Session
http://finance.yahoo.com/news/hyperion-therapeutics-report-results-halt-225621921.html
SIA 'SuperMan' charts.
http://investorshub.advfn.com/The-Golden-Cross-&-Bags-of-10!-24957/
ABT: http://stockcharts.com/h-sc/ui?s=ABT&p=D&b=5&g=0&id=p19982321839
AAPL:http://stockcharts.com/h-sc/ui?s=AAPL&p=D&b=5&g=0&id=p35611121956
WMT:http://stockcharts.com/h-sc/ui?s=AAPL&p=D&b=5&g=0&id=p35611121956
EBAY: http://stockcharts.com/h-sc/ui?s=EBAY&p=D&b=5&g=0&id=p63067035539
TJX:http://stockcharts.com/h-sc/ui?s=TJX&p=D&yr=1&mn=0&dy=0&id=p66917575952
ALGN. Align Technology to Announce Third Quarter Fiscal 2012 Results on October 17, 2012
http://finance.yahoo.com/news/align-technology-announce-third-quarter-231030885.html
RSMD. Resmed Announces Conference Call And Webcast To Discuss First Quarter 2013 Results
http://finance.yahoo.com/news/resmed-announces-conference-call-webcast-230000417.html
TSRO. TESARO Announces Clearance of Investigational New Drug Application for TSR-011
Company Plans to Proceed With a Phase 1/2 Clinical Study of the Anaplastic Lymphoma Kinase (ALK) Inhibitor TSR-011
http://finance.yahoo.com/news/tesaro-announces-clearance-investigational-drug-203000058.html
Thank you for the heads up. Are you in this play and if so for how long? Thanks, joe
Nice, I am fond of the 1 to 3 day swing trade off of the oversold position. always get out and try never to stay in too long. Played THLD this week. Bought 1000 shares at 6.5 and bought another at 6.00 and sold today at 6.70 for about a 500 dollar return. second time on THLD, made about 1000 on the last oversold position I took in THLD a few weeks ago. Might consider playing THLD on a regular basis since I actually like the company. Good luck with your trades, joe
SYT. chart.
website. http://www.syngenta-us.com/home.aspx
COV. Mallinckrodt, the Pharmaceuticals business of Covidien (COV), today announced that it has completed its acquisition of CNS Therapeutics, Inc. for approximately $100 million
http://finance.yahoo.com/news/mallinckrodt-completes-acquisition-cns-therapeutics-123000209.html
MACK. Merrimack Pharmaceuticals' Therapies Show Promise In Certain Advanced Breast, Gastric And Gynecologic Cancers
Phase 1 Study Results Presented at ESMO 2012 Congress Show ErbB3 as Potential Therapeutic Target
http://finance.yahoo.com/news/merrimack-pharmaceuticals-therapies-show-promise-123000324.html
USNA. USANA Optimizers BiOmega™ Gets Seal Of Approval From ConsumerLab.com
http://finance.yahoo.com/news/usana-optimizers-biomega-gets-seal-121200419.html
CBLI. Cleveland BioLabs and Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma
http://finance.yahoo.com/news/cleveland-biolabs-incuron-announce-cbl0102-120000743.html
ATRS. Antares Pharma Receives Development Milestone Payment
Company’s Pipeline Continues to Advance
http://finance.yahoo.com/news/antares-pharma-receives-development-milestone-110000638.html
http://stockcharts.com/c-sc/sc?s=ATRS&p=W&yr=1&mn=0&dy=0&i=t79557132186&r=1349179147930
2012 Nobel Prize Announcements Live Stream
http://finance.yahoo.com/news/2012-nobel-prize-announcements-live-110000801.html
STOCKHOLM, October 2, 2012 /PRNewswire/ --
?You can watch the live stream of the 2012 Nobel Prize announcements as the news breaks on Nobelprize.org, the official website of the Nobel Prize, with live coverage from official press conferences and exclusive interviews with experts, including alerts on social media such as Twitter and Facebook.
The 2012 Nobel Prize announcements within Physiology or Medicine, Physics, Chemistry, Literature, Peace and the Prize in Economic Sciences will be live streamed on Nobelprize.org. The first announcement, for the Nobel Prize in Physiology or Medicine, is scheduled on Monday, 8 October 11:30 a.m. CET at the earliest (see the full timetable of announcements). http://bit.ly/SkccIy Exclusive content such as interviews with members of Nobel Committees explaining this year's awarded achievements will also be streamed live.
Background information about the 2012 Nobel Laureates, their Nobel Prize-awarded work and official press releases from the Nobel Prize-awarding institutions will be immediately posted.
Directly after the Nobel Laureates have heard the news, Nobelprize.org conducts a telephone interview with them, capturing the Laureates' first reactions about the news. Nobelprize.org visitors can post greetings or messages to the new Laureates directly on the website.
In addition to the live stream on Nobelprize.org, you can follow the news in several ways:
Social Media. Keep up with the latest news and join the conversation about the 2012 Nobel Prizes on the Nobelprize.org Facebook page: http://www.facebook.com/Nobelprize.org, or Twitter: @nobelprize_org, http://twitter.com/Nobelprize_org (#NobelPrize).
Smartphone App. Download the official Nobel Prize mobile application available on Android Apps on Google Play. http://bit.ly/QCq3qz
Live Video Player. Do you want to live-stream the Nobel Prize Announcements on your web site, blog or social networks? Get the easy-to-add code that will allow you to embed the live video player. http://bit.ly/Tw6wOu
BSPM. Biostar Pharmaceuticals, Inc. To Manufacture And Supply Xijing Military Hospital With Three New Drugs
http://finance.yahoo.com/news/biostar-pharmaceuticals-inc-manufacture-supply-110000440.html
GNVC. GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program
http://finance.yahoo.com/news/genvec-enters-3-5-million-105500715.html
GNVC. GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program
http://finance.yahoo.com/news/genvec-enters-3-5-million-105500715.html
my pleasure comes from a good pick and early entry, with a ride to overvalued. i get a little swing trade in on the way up though.
I like seesawing stocks like THLD. Great runs on the upside after sell offs and sometimes you can get lucky on these swing trades and they get good news while you are holding them and they jump hard to the upside. Hope that happens with this puppy. Joe
thanks joe, i'm sure there will be trade opps between now and eoy.
Looks like basher news to me. THLD news was a rehash of last weeks news which brought the stock down to 5.9. Now they are rehashing ghe news and the stock is getting hit again. i expect the stock to go back up to over 7 by the weeks end. Interesting bit of manipulation on this seesawing stock price. I nailed last week off the low and am back in today to see if it repeats with a couple of green days. Joe
Thanks umiak. I will take that over to the medical boards.
Cloud saves health care time and money-biotech
http://www.npr.org/blogs/alltechconsidered/2012/10/01/162080613/cloud-computing-saves-health-care-industry-time-and-money
qwerty. I don't like DRL right now either.
$DRL - possible bounce back already?
I'm not convinced yet but I was / am expecting support around 80/90
Which was a short live visit as of today
SIA-Chart on WST : Very Bullish and on cruise control : Besides having a superman show up, which happens when the stock goes 5% above its 100 day moving average. We also have a super cross show last year up which means that the 50 day moving average has consistently stayed above the 100 day moving average, which is also very bullish and means that buyers are coming in big time.
WST. West Increases Quarterly Dividend to $0.19
http://finance.yahoo.com/news/west-increases-quarterly-dividend-0-203736402.html
AVY. Avery Dennison Announces 510(k) Clearance of New Chlorhexidine Gluconate (CHG) Transparent Film Dressing
http://finance.yahoo.com/news/avery-dennison-announces-510-k-151500736.html
PRGO. Perrigo Closes Acquisition Of Sergeant's Pet Care Products
http://finance.yahoo.com/news/perrigo-closes-acquisition-sergeants-pet-142000906.html
CLSN--company has consistently said phase 111 endpoint would be reached in Q4 2013. The phase 11 update re-enforces what we already know about phase 111 is going.
Celsion Announces Independent Data Monitoring Committee Completes Last Intermediate Review of Phase III HEAT Study of ThermoDox(R) in Primary Liver Cancer Prior to Final Data
380 PFS Events Projected for the Fourth Quarter of 2012 With Announcement of Top Line Results Following Data Monitoring Committee's Review
LAWRENCEVILLE, NJ -- (Marketwire) -- 09/14/12 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that the independent Data Monitoring Committee (DMC) for the Company's HEAT Study, a fully enrolled, multinational, double-blind, placebo-controlled, pivotal Phase III trial of ThermoDox® in combination with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC or primary liver cancer), has completed a regularly scheduled review of all 701 patients enrolled in the trial and has unanimously recommended that the HEAT Study continue according to protocol to its final data readout. The HEAT Study is being conducted under a Special Protocol Assessment (SPA) agreed to with the U.S. Food and Drug Administration (FDA).
The primary endpoint for the HEAT Study, progression-free survival (PFS), is defined in the SPA. A total of 380 PFS events are required to reach the unblinding and planned final analysis of the study. Celsion reconfirmed that 380 PFS events are projected to occur in the fourth quarter of 2012, with top line results announced following DMC review and confirmation.
The DMC has reviewed study data at regular intervals, with the primary responsibilities of ensuring the safety of all patients enrolled in the study, the quality of the data collected, and the continued scientific validity of the study design. As part of its review of all 701 patients, the DMC monitored a quality matrix relating to the total clinical data set, confirming the timely collection of data, that all data are current as well as other data collection and quality criteria.
"We sincerely thank the DMC for their diligent work in ensuring the quality and consistency of data from all 701 patients in the HEAT Study, as we approach the announcement of top line results," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "The HEAT Study is the single largest study ever conducted in intermediate-stage primary liver cancer, the largest unaddressed cancer in oncology today. Celsion is well prepared for the outcome of the HEAT Study, with the regulatory, manufacturing, financial and commercial plans and resources in place to ensure success. We look forward to the next steps for ThermoDox® and remain confident in its potential to provide a new and important therapeutic option for patients with this disease."
The HEAT Study, in addition to being conducted under an FDA Special Protocol Assessment, has received FDA Fast Track Designation and has been designated as a Priority Trial for liver cancer by the National Institutes of Health. ThermoDox® has been granted orphan drug designation in both the U.S. and Europe. The European Medicines Agency (EMA) has confirmed the HEAT Study provides an acceptable basis for submission of a marketing authorization application (MAA) for centralized review and approval. In addition to meeting the U.S. FDA and European EMA enrollment objectives, the HEAT Study has also enrolled a sufficient number of patients to support registrational filings in China, South Korea and Taiwan, three other large and important markets for ThermoDox®.
About Primary Liver Cancer
Primary liver cancer is one of the most deadly forms of cancer and ranks as the fifth most common solid tumor cancer. The incidence of primary liver cancer today is approximately 26,000 cases per year in the United States, approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 750,000 cases per year, 55 percent of which are in China, due to the high prevalence of Hepatitis B and C in developing countries. The World Health Organization estimates that primary liver cancer may become the number one cancer worldwide, surpassing lung cancer, by 2020.
About ThermoDox® and the Phase III HEAT Study
ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox® is administered intravenously in combination with Radio Frequency Ablation (RFA). Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.
For primary liver cancer, ThermoDox® is being evaluated in a global, multi-center, randomized, pivotal Phase III HEAT Study at 79 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival with a secondary confirmatory endpoint of overall survival. Additional information on the Company's ThermoDox® clinical studies may be found at www.clinicaltrials.gov.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.
For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Celsion Investor Contact
David Pitts
Argot Partners
212-600-1902
Email Contact
Source: Celsion Corporation
THLD--personally, i have been wondering why not more action in the lt options? and why not some 2014's? if they introduce some of those i will start taking a closer look, at the company.
umiak. your THLD post is good look-see info
for folks to decide on for themselves, eh.
Part of a well rounded look at a company. Thanks.
THLD--VIENNA (TheStreet) -- Threshold Pharmaceuticals (THLD) presented new data Saturday showing how pancreatic cancer patients who "crossed over" in a mid-stage clinical trial of TH-302 may have hampered the drug's ability to demonstrate a stronger improvement on overall survival.
Facebook, Apple, RIM, Sirius: Tech PremarketRIM, Facebook, Micron: Tech PremarketYahoo!, RIM, Sirius, Apple: Tech Premarket
More from Adam Feuerstein
Celgene's Abraxane Is Talk of European Cancer ConfabExelixis: Big-Money Raise Leaves Stock in RutBiotech Stock Mailbag: YM Bio, Hemispherx, Navidea
When these crossover patients were excluded from the analysis of the phase II study, the survival benefit attributable to TH-302 improved.
The new analysis was an effort by Threshold to alleviate investor concerns about the future of TH-302. The company's stock price has fallen by 20% over the past two weeks because of worries that TH-302 would not help patients live longer in a larger, phase III trial scheduled to start soon.
CLSN--Celsion Announces DIGNITY Study Data Presented at 2012 Congress for European Society of Medical Oncology
Updated Safety and Efficacy Results With ThermoDox(R) Plus Hyperthermia for Breast Cancer at the Chest Wall
LAWRENCEVILLE, NJ -- (Marketwire) -- 10/01/12 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the presentation of Phase I results from the Company's Phase I/II DIGNITY study of ThermoDox® in Breast Cancer Recurrences at the Chest Wall at the ESMO 2012 Congress, the annual conference for the European Society of Medical Oncology held in Vienna, Austria September 28 to October 2, 2012. The presentation, titled "Breast Cancer Recurrences at the Chest Wall (BCRCW) When Standard Treatments (Tx) Have Failed: Lyso-thermosensitive liposomal doxorubicin (LTLD) + Mild Local Hyperthermia (MLH)," was delivered by Professor Hope S. Rugo, MD, from the UCSF School of Medicine, and provided a clinical update of the Phase I/II DIGNITY trial studying ThermoDox® for breast cancer. A copy of the poster presentation is available at www.celsion.com/docs/pipeline_presentations.
In the Phase I portion of the DIGNITY study, a highly treatment-refractory BCRCW patient population was treated using ThermoDox® in combination with MLH for superficial lesions < 3cm depth that have failed standard treatment. The study was designed to determine the Maximum Tolerated Dose (MTD) or confirm 50 mg/m2 as acceptable, evaluate safety, Sparse PK sampling, and determine early effects of ThermoDox® in combination with MLH. A total of 11 subjects were treated. Drug Related Adverse Events were consistent with the known safety profile of doxorubicin including myelosuppression, alopecia, fatigue, and nausea. Reversible myelosuppression was the most frequently observed effect, effectively managed with ASCO g-CSF treatment recommendations. Clinically meaningful responses were observed, including a target lesion response rate of 45% without local progression (complete response 9.1%, n=1/11, partial response 36.4%, n=4/11). The study found that 50 mg/m2 is the acceptable Phase 2 dose, as determined by independent review. Based on these results, Celsion is continuing into a Phase 2 study, to include additional clinical research sites.
Professor Rugo commented, "BCRCW patients, who in this study had an average of over four prior regimens, often have limited or no treatment options, underscoring a significant unmet medical need in this population. The initial experience with hyperthermia and ThermoDox® demonstrates the tolerability of the regimen in these patients as well as early efficacy signals, providing strong support for moving into a larger study."
"Breast cancer recurrence at the chest wall has a poor prognosis, is difficult to treat and is characterized by disfigurement, pain, and restriction of movement. These results, therefore, particularly in such highly refractory patients, are encouraging," said Nicholas Borys, Celsion's Vice President and Chief Medical Officer. "These data are further evidence of ThermoDox®'s broad potential clinical value across different cancers, including the ability to provide a new tool against aggressive, superficial tumors. We look forward to rapidly recruiting patients for the Phase 2 portion of DIGNITY as results from our Phase 3 HEAT study of ThermoDox® in primary liver cancer become available."
National Breast Cancer Awareness Month
Professor Rugo's presentation of data from the DIGNITY Study comes at a very poignant time for BCRCW patients. Celsion notes that October is National Breast Cancer Awareness Month, and urges the breast cancer research community to make the public aware of our promising trial in this difficult to treat form of cancer.
About ThermoDox® and the Phase III HEAT Study
ThermoDox® is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers. In the HEAT Study, ThermoDox® is administered intravenously in combination with Radio Frequency Ablation (RFA). Localized mild hyperthermia (39.5 - 42 degrees Celsius) created by the RFA releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.
For primary liver cancer, ThermoDox® is being evaluated in a global, multi-center, randomized, pivotal Phase III HEAT Study at 79 clinical sites under an FDA Special Protocol Assessment. The study is designed to evaluate the efficacy of ThermoDox® in combination with RFA when compared to patients who receive RFA alone as the control. The primary endpoint for the study is progression-free survival with a secondary confirmatory endpoint of overall survival. Additional information on the Company's ThermoDox® clinical studies may be found at www.clinicaltrials.gov.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital, the Beijing Cancer Hospital and the University of Oxford.
For more information on Celsion, visit our website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
Investor Contact
David Pitts
Argot Partners
212-600-1902
Email Contact
FONR. FONAR Reports Record Profits From Operations for Fiscal 2012; Net Income Doubles From Fiscal 2011; Revenues Increase 19% to $39.4 Million
http://finance.yahoo.com/news/fonar-reports-record-profits-operations-110000649.html
SURG. Fourth Quarter Summary:
Total sales were $16.9 million, a year-over-year increase of 7.7% and a 15.7% sequential increase over third quarter of fiscal 2012.
OEM sales increased 26.8% and Ophthalmic sales declined 3.9% year-over-year.
Domestic sales increased 12.1% and International sales declined 3.0% year-over-year.
Disposable products sales increased 8.8% and capital equipment sales increased 1.6%.
GAAP EPS was $0.08 versus $0.08 for the comparable period last year.
Cash flow from operations was $547,000.
Fiscal Year Summary:
Total sales were $60.0 million, up 7.8% year-over-year.
OEM sales increased 23.2% and Ophthalmic sales increased 2.0% year-over-year.
Domestic sales increased 12.9% and International sales declined 4.2% year-over-year.
GAAP EPS from continuing operations* was $0.24 versus $0.23 in fiscal year 2011.
http://finance.yahoo.com/news/synergetics-reports-record-quarterly-sales-103000301.html
APRI. Apricus Biosciences Announces Intent to File NDS for MycoVa(TM) in Canada
Health Canada Agrees to Review of Existing Phase 3 Clinical Data Package Based on the Re-Analysis of the Secondary Endpoints
http://finance.yahoo.com/news/apricus-biosciences-announces-intent-file-100000550.html
Followers
|
7
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
564
|
Created
|
09/23/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |